Evidence map›Paper›PMID 26205180›Full record

GuidelineModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2015

Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group.

Elena Provenzano, Veerle Bossuyt, Giuseppe Viale, David Cameron, Sunil Badve, Carsten Denkert, Gaëtan MacGrogan, Frédérique Penault-Llorca, Judy Boughey, Giuseppe Curigliano and 10 more

Open access · bronzeAbstract readPractice Guideline
PubMed Publisher
In one paragraph

Guideline in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed, 5 pooled it
8.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

131 citing papers in PubMed, 5 syntheses or guidelines pooled it, 280 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. The accuracy ofEuropean radiology · 2017
    Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016
    Trial
  15. Article
  16. Review
  17. Article
  18. Prognostic value of post-neoadjuvant pathological response and residual disease in early breast cancer: a real-world cohort study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  19. Article
  20. Review

71 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 18 institutions in 6 countries.

Elena ProvenzanoDepartment of Histopathology and NIH Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Cambridge, UK.
Veerle BossuytDepartment of Pathology, Yale University, New Haven, CT, USA.
Giuseppe VialeDepartment of Pathology, European Institute of Oncology and University of Milan, Milan, Italy.
David CameronEdinburgh Cancer Research UK Centre,University of Edinburgh, Edinburgh, UK.
Sunil BadveDepartment of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
Carsten DenkertInstitute of Pathology, Charité Hospital, Berlin, Germany.
Gaëtan MacGroganDepartment of Biopathology, Institut Bergonié, Bordeaux, France.
Frédérique Penault-LlorcaDepartment of Pathology, Centre Jean Perrin and Université d'Auvergne, Clermont-Ferrand, France.
Judy BougheyDivision of Subspecialty General Surgery, Mayo Clinic, Rochester, MN, USA.
Giuseppe CuriglianoEarly Drug Development for Innovative Therapies Division, European Institute of Oncology, Milan, Italy.
J Michael DixonEdinburgh Breast Unit, Western General Hospital, Edinburgh, UK.
Laura EssermanCarol Franc Buck Breast Care Center, University of California, San Francisco, CA, USA.
Gerd FastnerDepartment of Radiotherapy and Radiation Oncology, Landeskrankenhaus, Paracelsus Medical University, Salzburg, Austria.
Thorsten KuehnDepartment of Gynecology and Obstetrics, Interdisciplinary Breast Center, Klinikum Esslingen, Esslingen, Germany.
Florentia PeintingerInstitute of Pathology, Medical University of Graz, Graz, Austria.
Gunter von MinckwitzGerman Breast Group, Neu-Isenburg, and Department of Gynecology and Obstetrics, University Women's Hospital, Frankfurt, Germany.
Julia WhiteDepartment of Radiation Oncology, Ohio State University, Columbus, OH, USA.ORCID http://orcid.org/0000-0001-6624-5631
Wei YangDepartment of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
W Fraser SymmansDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Residual Disease Characterization Working Group of the Breast International Group-North American Breast Cancer Group Collaboration
The University of Texas MD Anderson Cancer Center · USAddenbrooke's Hospital · GBCentre Jean Perrin · FRCharité - Universitätsmedizin Berlin · DEEdinburgh Cancer Research · GBEuropean Institute of Oncology · ITGerman Breast group · DEIndiana University School of MedicineInstitut Bergonié · FRKlinikum Esslingen · DEMayo Clinic in Arizona · USMedical University of Graz · ATParacelsus Medical University · ATThe Ohio State University · USUniversity of California, San Francisco · USUniversity of Milan · ITWestern General Hospital · GBYale University · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Cancer Research UK 11010
6 · The paper itself

Abstract

Neoadjuvant systemic therapy is being used increasingly in the treatment of early-stage breast cancer. Response, in the form of pathological complete response, is a validated and evaluable surrogate end point of survival after neoadjuvant therapy. Thus, pathological complete response has become a primary end point for clinical trials. However, there is a current lack of uniformity in the definition of pathological complete response. A review of standard operating procedures used by 28 major neoadjuvant breast cancer trials and/or 25 sites involved in such trials identified marked variability in specimen handling and histologic reporting. An international working group was convened to develop practical recommendations for the pathologic assessment of residual disease in neoadjuvant clinical trials of breast cancer and information expected from pathology reports. Systematic sampling of areas identified by informed mapping of the specimen and close correlation with radiological findings is preferable to overly exhaustive sampling, and permits taking tissue samples for translational research. Controversial areas are discussed, including measurement of lesion size, reporting of lymphovascular space invasion and the presence of isolated tumor cells in lymph nodes after neoadjuvant therapy, and retesting of markers after treatment. If there has been a pathological complete response, this must be clearly stated, and the presence/absence of residual ductal carcinoma in situ must be described. When there is residual invasive carcinoma, a comment must be made as to the presence/absence of chemotherapy effect in the breast and lymph nodes. The Residual Cancer Burden is the preferred method for quantifying residual disease in neoadjuvant clinical trials in breast cancer; other methods can be included per trial protocols and regional preference. Posttreatment tumor staging using the Tumor-Node-Metastasis system should be included. These recommendations for standardized pathological evaluation and reporting of neoadjuvant breast cancer specimens should improve prognostication for individual patients and allow comparison of treatment outcomes within and across clinical trials.

Indexed as

Neoadjuvant TherapyBreast NeoplasmsClinical Trials as TopicFemaleHumansPathology, ClinicalResearch DesignSpecimen Handling

Identifiers

PMID26205180
OpenAlexW1891489226

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.